{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:45Z","timestamp":1791264525974,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.bone.2008.10.047","type":"journal-article","created":{"date-parts":[[2008,11,9]],"date-time":"2008-11-09T05:06:08Z","timestamp":1226207168000},"page":"380-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Inhibition of bone resorption and growth of breast cancer in the bone microenvironment"],"prefix":"10.1016","volume":"44","author":[{"given":"Jeroen T.","family":"Buijs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens W.G.M.","family":"L\u00f6wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabri","family":"van der Pluijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2008.10.047_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2008.10.047_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1677\/erc.1.00543","article-title":"Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone","volume":"12","author":"Clines","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib5","first-page":"106","article-title":"Cancer statistics","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bone.2008.10.047_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.bone.2008.10.047_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ijc.2910520522","article-title":"Effect of IL-1 on experimental bone\/bone-marrow metastases","volume":"52","author":"Arguello","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00133470","article-title":"Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone","volume":"10","author":"Kostenuik","year":"1992","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bone.2008.10.047_bib9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/en.2004-1211","article-title":"Bone turnover mediates preferential localization of prostate cancer in the skeleton","volume":"146","author":"Schneider","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2008.10.047_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2008.10.047_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib12","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.10.047_bib13","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","article-title":"Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo","volume":"65","author":"van der Pluijm","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.10.047_bib14","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2008.10.047_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6","article-title":"Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice","volume":"77","author":"Sasaki","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2008.10.047_bib17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0002-9440(10)64934-6","article-title":"Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease","volume":"160","author":"Wetterwald","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2008.10.047_bib18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0002-9440(10)61773-7","article-title":"Urokinase-receptor\/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo","volume":"159","author":"van der Pluijm","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2008.10.047_bib19","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.1999.14.9.1478","article-title":"A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3","volume":"14","author":"Morony","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2008.10.047_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1359\/jbmr.2001.16.6.1077","article-title":"Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases","volume":"16","author":"van der Pluijm","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.10.047_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s002230010047","article-title":"Alendronate disturbs vesicular trafficking in osteoclasts","volume":"70","author":"Alakangas","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2008.10.047_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen\u2013containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bone.2008.10.047_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","article-title":"Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour\u2013host interface","volume":"411","author":"Liotta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.10.047_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ortho\/25.2.101","article-title":"Bone remodelling","volume":"25","author":"Hill","year":"1998","journal-title":"Br. J. Orthod."},{"key":"10.1016\/j.bone.2008.10.047_bib26","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2008.10.047_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.addr.2004.12.018","article-title":"Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics","volume":"57","author":"Vaananen","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bone.2008.10.047_bib28","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1200\/JCO.2005.02.9579","article-title":"Bisphosphonates for treatment and prevention of bone metastases","volume":"23","author":"Michaelson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdi162","article-title":"Bisphosphonates in breast cancer","volume":"16","author":"Coleman","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0277-5379(86)90117-3","article-title":"Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment","volume":"22","author":"Elte","year":"1986","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib32","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib34","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bone.2008.10.047_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib37","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.10.047_bib39","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","article-title":"Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions","volume":"16","author":"Peyruchaud","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.10.047_bib40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.10.047_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bone.2008.10.047_bib42","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2008.10.047_bib43","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2008.10.047_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bone.2008.10.047_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ncponc0381","article-title":"Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis","volume":"3","author":"Blair","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.bone.2008.10.047_bib46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.11125","article-title":"Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease","volume":"97","author":"Croucher","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.10.047_bib47","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.10.047_bib48","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2008.10.047_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2008.10.047_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2007","journal-title":"Clin. Exp. Metastasis"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208008636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208008636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:37:45Z","timestamp":1762659465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328208008636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S8756328208008636"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2008.10.047","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2008.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}